|
⚲
|
| Message |
|---|
| Happy Holidays!! thanks for using AUM13F!! |
| Avoro Capital Advisors LLC
✚
|
|
|---|---|
| CRD # | 154091 |
| SEC # | 801-74391 |
| CIK # | 0001633313 |
| AUM | $9.9 B (2025-03-20) |
| Employees | 19 (58% Investors, 0% Brokers) |
| Phone | 212-937-4970 |
| Address | 110 Greene Street New York, NY 10012 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Ascendis Pharma A/S | 0.9 | ||
| United Therapeutics Corp | 0.7 | ||
| Argenx SE | 0.6 | ||
| Synta Pharmaceuticals Corp | 0.6 | ||
| Krystal Biotech Inc | 0.4 | ||
| Kymera Therapeutics Inc | 0.3 | ||
| Apellis Pharmaceuticals Inc | 0.2 | ||
| Avidity Biosciences Inc | 0.2 | ||
| Helix Acquisition Corp | 0.2 | ||
| Akero Therapeutics Inc | 0.2 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold ($M) | AUM ($M) |
|---|---|---|---|---|
| VC | Avoro Ventures Fund LP | [2021-03-23] | 178.4 | 178.0 |
| VC | venBio Global Strategic Fund II LP | [2016-03-29] | 337.0 | 315.2 |
| HF | Avoro Life Sciences Fund LLC | [2012-02-22] | 2,110.0 | 9,713.1 |
| VC | venBio Global Strategic Fund LP | [2012-02-22] | 177.0 | 178.8 |
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 3 | 9.9 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 3 | 9.9 |
| By Discretionary | ||
| Discretionary | 3 | 9.9 |
| Non-Discretionary | 0 | 0.0 |
| Total | 3 | 9.9 |
| By Non-United States Persons | ||
| Non-United States Persons | 4.9 | |
| United States Persons | 5.0 | |
| Total | 3 | 9.9 |
| EDGAR Form | CIK | 2011 - 2025 |
|---|---|---|
| 13F-HR | [0001633313] | |
| 3 | [0001633313] | |
| 4 | [0001633313] | |
| SC 13D | [0001633313] | |
| SC 13G | [0001633313] |
| Form 3/4/5 Subject | 2011 - 2025 |
|---|---|
| Whitehawk Therapeutics, Inc. | |
| Avoro Ventures LLC | |
| Aghazadeh Behzad | |
| Avoro Capital Advisors LLC | |
| CymaBay Therapeutics, Inc. | |
| Immunomedics Inc | |
| Mirati Therapeutics, Inc. |
| Comparable Firms | State | AUM ($B) |
|---|---|---|
|
Corbin Capital Partners LP
✚
|
NY | 10.5 |
|
400 Capital Management LLC
✚
|
NY | 10.4 |
|
SRS Investment Management LLC
✚
|
NY | 10.4 |
|
Maverick Capital Ltd
✚
|
TX | 10.3 |
|
Darsana Capital Partners LP
✚
|
NY | 10.0 |
|
Orchard Global Asset Management LLP
✚
|
9.9 | |
|
RTW Investments LP
✚
|
NY | 9.8 |
|
Magnitude Capital LLC
✚
|
NY | 9.6 |
|
Pacific Private Fund Advisors LLC
✚
|
CA | 9.5 |
|
Blackstone Multi-Asset Advisors LLC
✚
|
NY | 9.2 |